Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Leases (2017 - 2023)

Aclaris Therapeutics (ACRS) has 5 years of Current Leases data on record, last reported at $426000.0 in Q4 2023.

  • For Q4 2023, Current Leases fell 37.72% year-over-year to $426000.0; the TTM value through Dec 2023 reached $426000.0, down 37.72%, while the annual FY2023 figure was $426000.0, 37.72% down from the prior year.
  • Current Leases reached $426000.0 in Q4 2023 per ACRS's latest filing, up from $310000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $766000.0 in Q3 2022 and bottomed at $310000.0 in Q3 2023.
  • Average Current Leases over 3 years is $585125.0, with a median of $643500.0 recorded in 2022.
  • Peak YoY movement for Current Leases: decreased 1.3% in 2022, then plummeted 59.53% in 2023.
  • A 3-year view of Current Leases shows it stood at $693000.0 in 2021, then fell by 1.3% to $684000.0 in 2022, then tumbled by 37.72% to $426000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Current Leases were $426000.0 in Q4 2023, $310000.0 in Q3 2023, and $458000.0 in Q2 2023.